AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06719908 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: AFA-281 is a small molecule, orally available
Description: This is a study to evaluate the interaction of AFA-281 with alcohol
Study NCT06719908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFA-281 is a small molecule, orally available
Description: This is a study to evaluate the interaction of AFA-281 with alcohol
Study NCT06719908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AFA-281 is a small molecule, orally available
Description: This is a study to evaluate the interaction of AFA-281 with alcohol
Study NCT06719908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol (Ethanol)
Description: Alcohol will be administered in combination with AFA-281 or AFA-281 placebo
Study NCT06719908 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Alcohol (Ethanol)
Description: Alcohol will be administered in combination with AFA-281 or AFA-281 placebo
Study NCT06719908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol (Ethanol)
Description: Alcohol will be administered in combination with AFA-281 or AFA-281 placebo
Study NCT06721286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teripalimab
Description: 240mg intravenous injection, D1, q3w, for 9 weeks (3 cycles)
Study NCT06721286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Cisplatin
Description: Gemcitabine 1000mg/m2 + cisplatin 25mg/m2, D1\&D8, q3w, for 9 weeks (3 cycles)
Study NCT06721286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical resection
Study NCT06720922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)
Description: MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
Study NCT05418556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: DAPT strategy
Study NCT05418556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: DAPT strategy
Study NCT06276478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-video
Description: Video administration for the explanation of the dental procedures followed by verbal instructions.
Study NCT06276478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal instructions
Description: Only verbal instructions will be administered for the explanation of the dental procedures
Study NCT04953923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedazuridine
Description: Tablet for oral administration
Study NCT05087173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: An interactive chatbot for patient decision aid A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
Study NCT04672824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 RVF
Description: Single dose ChAdOx1 vectored vaccine
Study NCT04672824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 0.5ml saline placebo
Study NCT06560255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid
Description: Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
Study NCT06560255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rape seed oil
Description: Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
Study NCT06330467 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: psychometric assessment
Description: Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.
Study NCT06330467 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: semi-structured clinical interview
Description: Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)
Study NCT06452797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ProVent-14 score
Description: A score to estimate one-year mortality for patients requiring at least 14 days of mechanical ventilation
Study NCT05104268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bocaliner
Description: Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
Study NCT05104268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bocaliner
Description: Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
Study NCT04953923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule for oral administration
Study NCT04953923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablet for oral administration
Study NCT06482047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling
Description: Moderate-intensity cycling on Ergoline Ergoselect 100
Study NCT06482047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity cycling
Description: Vigorous-intensity cycling on Ergoline Ergoselect 100
Study NCT06482047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted sitting
Description: Uninterrupted sitting in a quiet room
Study NCT04381468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pepinemab
Description: Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Study NCT04381468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Study NCT06039956 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel lymph Node Biopsy
Description: The SLNB will be performed with 5 ml of undiluted methylene blue injected in equal aliquots, peri-tumoral, followed by a 5-minute massage prior to skin incision. Sentinel nodes will be defined as those that have uptake / visible blue staining or suspicious palpable nodes at the discretion of the operating surgeon. Sentinel nodes will be placed in formalin and sent separately. This will be followed by an immediate completion ALND, which will be similarly placed in formalin and sent separately from the SLNB specimen. Specimen radiographs will be performed on all specimens to confirm location of clip within SLNB vs. ALND specimens.
Study NCT06121661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APPRAISE Trauma Clinical Decision Support System
Description: Real-time bedside decision-support system for trauma patient management
Study NCT06720922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery
Description: Traditional Open Surgery
Study NCT06719687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-driving robotic-assisted bronchoscope
Description: All procedures will be performed under general anesthesia with endotracheal intubation and mechanical ventilation. The self-driving robotic-assisted bronchoscope will automatically advance through airway to the target lesion according to the preoperative planning path under the guidance of electromagnetic navigation. After that, the bronchoscopist will use radial endobronchial ultrasound (rEBUS) to confirm the lesion localization. The choice of biopsy tools (eg. forceps, needles, brush, etc.) will be left to the discretion of the bronchoscopist.
Study NCT06721780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Participants randomised to wear AR headset
Description: Participants will use an AR headset that employs a distraction game specifically designed for children and young adults undergoing painful procedures.
Study NCT06721780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Participants randomised to wear VR headset
Description: Participants will utilise a VR headset, running a calming virtual environment or an interactive game during the dressing change.
Study NCT06721663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory environment stimulation therapy
Description: A Multi Sensory Environment is a dedicated space or room where sensory stimulation can be controlled (intensified or reduced), presented in isolation or combination, packaged for active or passive interaction
Study NCT05421715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TELEDUC-DIAB
Description: * Systematic monthly remote monitoring between traditional face-to-face consultations by a medical researcher using Kidia and My Diabby digital devices:~  * With downloading by the adolescent of all data on My Diabby platform (clinical data from diabetes monitoring)~ * Evaluation of adverse events related to the treatment of diabetes (hospitalizations and concomitant treatment)~ * Analysis of data collected via My Diabby and Kidia: glycemic balance, captured data, connection frequency, alerts and alarms, diabetes knowledge)~ * The proposal of a therapeutic education session according to the needs of the adolescent via the Kidia application~ * Treatment adaptation~* A follow-up in case there is an alert identified by the teenager, the relative or My Diabby/caregiver~  * The medical orientation of the patient according to the needs identified~ * A proposal for a therapeutic education session according to the needs of the adolescent via the Kidia application
Study NCT06389825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy diet
Description: 28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
Study NCT04995510 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: To evaluate your chronic obstructive pulmonary disease with Chronic Obstructive Pulmonary Disease assessment test, respiratory muscle strength with intraoral pressure measurement device, respiratory muscle endurance with increasing threshold load respiratory muscle endurance test, diaphragm thickness with ultrasound device, cardiorespiratory fitness with 6 Minute Walk Test, flexibility trunk lateral flexion test , back scratch test and sit and lie down test, muscle strength and endurance will be evaluated with push-up test, sit-up test, sit and stand test and hand grip strength, body composition will be evaluated by bioelectrical impedance analysis, physical activity will be questioned with the International Physical Activity Assessment Questionnaire, shortness of breath with the Mmrc Dyspnea Scale, and perception of fatigue and shortness of breath with the Modified Borg Scale.
Study NCT05514015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab combined with corticosteroids
Description: Induction therapy:~Rituximab intravenous infusion of 1g, d1, d15, combined with glucocorticoid therapy, oral prednisolone, initial dose of 0.5mg/(kg·d), once a day, after 8 weeks of treatment, reduce by 5mg every 4 weeks until 0.25mg/kg, this dose was maintained for 8 weeks, and then reduced by 2.5mg every 4 weeks, until 5-10mg is maintained, and the total course of treatment was about one year or so;
Study NCT05514015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Control group (treated with Rituximab monotherapy treatment) :Rituximab intravenous infusion of 1g, d1, d15
Study NCT04780893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modius Sleep
Description: The device utilizes a technology called vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
Study NCT04780893 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Modius Sleep
Description: The device utilizes a technology called vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
Study NCT05961046 — intervention group
Intervention type: DEVICE
Intervention: Vivity IOL
Description: Vivity IOL
Study NCT06266182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT intervention will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive a web-based intervention consisting of educational and practical tasks/activities. Participants will learn to recognize moments of choice (actions that lead towards values or away from them) and to use attention flexibly to free themselves from the power of thoughts, to open up and accept emotions, and to be able to determine what is important and take action in line with values. All of the tasks will be available in written form and audio. The ACT intervention is built from standard ACT exercises.
Study NCT06266182 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Education will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive information about post-transplant prescriptions along with exercises to support the implementation. Participants will learn about nutrition, personal hygiene, preventing infections, coping with fatigue, resuming activity, rest and sleep, engaging in social interactions, and sexual health. The content is prepared based on available guides for HCT recipients.
Study NCT04667637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: edaravone dexborneol
Description: Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
Study NCT04667637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edaravone dexborneol
Description: Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
Study NCT05783063 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active iTBS
Description: Mag-TD
Study NCT04431622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid amplification algorithms
Description: The investigators will use stimulus waveforms that have been amplified and recorded for each individual's hearing loss. These waveforms will be created using Desired Sensation Level, Version 5-C hearing aid targets on a continuum of increased signal manipulation. The NIH-funded open hearing aid platform will be used to provide precise control over hearing aid parameters to create waveforms with linear and fast-acting compression amplification. A third set of waveforms will be created using a current clinical hearing aid that uses typical noise reduction and compression parameters. Investigating the effects of hearing aid algorithms in young normal-hearing and older normal-hearing listeners will aid in interpretation of these effects in the older hearing-impaired listeners.
Study NCT05373511 — intervention group
Intervention type: OTHER
Intervention: 3D/4D spine and posture analysis DIERS FORMETRIC 4D ,The Biodex Balance System SD-
Description: 3D/4D spine and posture analysis DIERS FORMETRIC 4D for postural analysis assessment~,The Biodex Balance System SD- for balance assessment
Study NCT05104372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)
Description: Nasal washout and gargles
Study NCT05104372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)
Description: Nasal washout and gargles
Study NCT05554861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency rTMS Protocol
Description: It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist).
Study NCT05554861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS) Protocol
Description: It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTBS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist).
Study NCT05554861 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS Protocol
Description: It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.~After the daily sham rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist).
Study NCT05003986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Population 1: 800 mg Sparsentan (oral suspension)
Study NCT05003986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Population 2: 400 mg Sparsentan (oral suspension)
Study NCT05003986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Population 3: 400 mg Sparsentan (tablets)
Study NCT04598009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Taken orally (PO) twice a day (BID)
Study NCT04598009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Taken orally (PO) once a day (QD)
Study NCT06449339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.
Study NCT06721663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy intervention
Description: therapeutic balance training and functional therapeutic exercises
Study NCT05783063 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: Mag-TD
Study NCT06222502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Planning, Reminders, and Micro-Incentives
Description: Participants will schedule planned walks during weekly phone calls with study staff. Participants will receive reminders for planned walks and receive micro-incentives after completion.
Study NCT06222502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Participants in this group will receive health education tips during weekly phone calls with study staff.
Study NCT05301894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-827104
Description: T-type calcium channel blocker.
Study NCT05735717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
Study NCT05735717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5
Study NCT05735717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 50 mg/m2 IV on days -4 to -2
Study NCT05735717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 200 mg/m2 intravenous given once on day-1